300 related articles for article (PubMed ID: 11258897)
1. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Xiao Q; Giguere J; Parisien M; Jeng W; St-Pierre SA; Brubaker PL; Wheeler MB
Biochemistry; 2001 Mar; 40(9):2860-9. PubMed ID: 11258897
[TBL] [Abstract][Full Text] [Related]
2. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
4. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
5. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
6. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.
Sarrauste de Menthière C; Chavanieu A; Grassy G; Dalle S; Salazar G; Kervran A; Pfeiffer B; Renard P; Delagrange P; Manechez D; Bakes D; Ktorza A; Calas B
Eur J Med Chem; 2004 Jun; 39(6):473-80. PubMed ID: 15183905
[TBL] [Abstract][Full Text] [Related]
8. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
[TBL] [Abstract][Full Text] [Related]
9. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants for activity of glucagon-like peptide-2.
DaCambra MP; Yusta B; Sumner-Smith M; Crivici A; Drucker DJ; Brubaker PL
Biochemistry; 2000 Aug; 39(30):8888-94. PubMed ID: 10913301
[TBL] [Abstract][Full Text] [Related]
12. [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.
Hinke SA; Manhart S; Kühn-Wache K; Nian C; Demuth HU; Pederson RA; McIntosh CH
J Biol Chem; 2004 Feb; 279(6):3998-4006. PubMed ID: 14610075
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of GLP-1-analogues with N-terminal modifications.
Siegel EG; Gallwitz B; Scharf G; Mentlein R; Morys-Wortmann C; Fölsch UR; Schrezenmeir J; Drescher K; Schmidt WE
Regul Pept; 1999 Feb; 79(2-3):93-102. PubMed ID: 10100921
[TBL] [Abstract][Full Text] [Related]
16. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
17. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
18. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
[TBL] [Abstract][Full Text] [Related]
19. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Al-Sabah S; Donnelly D
Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
[TBL] [Abstract][Full Text] [Related]
20. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge.
López de Maturana R; Donnelly D
FEBS Lett; 2002 Oct; 530(1-3):244-8. PubMed ID: 12387900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]